Astria Therapeutics Shares Rise Following Update on In-Development Drugs
Press Release: Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Express News | Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Express News | Astria Therapeutics Q1 Income From Operations USD -36.995 Million
Express News | Astria Therapeutics Q1 EPS USD -0.58
Express News | Astria Therapeutics Q1 Operating Expenses USD 36.995 Million
Express News | Astria Therapeutics Q1 Net Income USD -33.709 Million
Astria Therapeutics Inc | 10-Q: Quarterly report
Astria Therapeutics Publishes Navenibart Phase 1a Healthy Subject Results In Annals of Allergy, Asthma & Immunology
Express News | Cantor Fitzgerald Initiates Coverage On Astria Therapeutics With Overweight Rating, Announces Price Target of $47
New Analyst Forecast: $ATXS Given 'Overweight' Rating
JMP Securities Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $26
Top Premarket Decliners
Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation
Wedbush Initiates Astria Therapeutics Inc(ATXS.US) With Buy Rating, Announces Target Price $28
Oppenheimer Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $32
Wedbush Adjusts Price Target on Astria Therapeutics to $28 From $27, Keeps Outperform Rating
Astria Therapeutics Inc | 10-K: FY2024 Annual Report
Astria TherapeuticS GAAP EPS of -$1.68 Beats by $0.01
Astria Therapeutics Inc | 8-K: Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update